These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18642120)

  • 1. Outcome study of first-episode schizophrenia in a developing country: quality of life and antipsychotics.
    Chee KY
    Soc Psychiatry Psychiatr Epidemiol; 2009 Feb; 44(2):143-50. PubMed ID: 18642120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of psychological symptoms, antipsychotics and social data with psychosocial function in schizophrenia patients in Malaysia.
    Norlelawati AT; Kartini A; Norsidah K; Ramli M; Wan Azizi WS; Tariq AR
    Asia Pac Psychiatry; 2015 Mar; 7(1):45-53. PubMed ID: 23857669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride.
    Nuss P; Tessier C
    Curr Med Res Opin; 2010 Apr; 26(4):787-801. PubMed ID: 20121655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of subjective quality of life in first-episode schizophrenia: perspective from Malaysia.
    Chee KY
    Early Interv Psychiatry; 2010 May; 4(2):111-8. PubMed ID: 20536966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
    Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
    Lin CH; Wang FC; Lin SC; Huang YH; Chen CC; Lane HY
    Int Clin Psychopharmacol; 2013 Sep; 28(5):267-74. PubMed ID: 23778382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.
    Hofer A; Rettenbacher MA; Edlinger M; Huber R; Bodner T; Kemmler G; Sachs G; Fleischhacker WW
    Pharmacopsychiatry; 2007 Jan; 40(1):1-8. PubMed ID: 17327953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
    Leucht S; Pitschel-Walz G; Engel RR; Kissling W
    Am J Psychiatry; 2002 Feb; 159(2):180-90. PubMed ID: 11823257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia.
    Kaneda Y
    Clin Neuropharmacol; 2003; 26(4):182-4. PubMed ID: 12897637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.
    Herrera-Estrella M; Apiquian R; Fresan A; Sanchez-Torres I
    BMC Psychiatry; 2005 May; 5():22. PubMed ID: 15869707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.
    Ritsner M; Gibel A; Perelroyzen G; Kurs R; Jabarin M; Ratner Y
    J Clin Psychopharmacol; 2004 Dec; 24(6):582-91. PubMed ID: 15538118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New generation antipsychotics for first episode schizophrenia.
    Rummel C; Hamann J; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2003; (4):CD004410. PubMed ID: 14584012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
    Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
    Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How do we choose between atypical antipsychotics? The advantages of amisulpride.
    Mortimer AM
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S21-5. PubMed ID: 14972081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
    Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
    Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.